Business
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile Full study data from both cohorts expected later this year BARCELONA, Spain, June 26, 2025 (GLOBE NEWSWIRE) -- The Australasi
About this update from Lisata Therapeutics, Inc.
[{"type":"image","alt":"Lisata Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Lisata Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y4XbqVAm8oIdeBK9.mjRkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363","width":300,"height":84}},"lazy":false},{"type":"text","content":"ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially","length":110,"tagName":"p"},{"type":"text","content":"Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group","length":144,"tagName":"p"},{"type":"text","content":"Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile","length":118,"tagName":"p"},{"type":"text","content":"Full study data from both cohorts expected later this year","length":58,"tagName":"p"},{"type":"text","content":"BARCELONA, Spain, June 26, 2025 (GLOBE NEWSWIRE) -- The Australasian Gastro-Intestinal Trials Group (“AGITG”), the NHMRC Clinical Trials Centre at the University of Sydney, and Lisata Therapeutics, Inc (“Lisata”, Nasdaq: LSTA), today announced promising positive preliminary Cohort B data from the ASCEND Phase 2b trial (NCT05042128) in metastatic pancreatic cancer, with AGITG sponsoring the study and Lisata providing funding. Dr. Andrew Dean, Study Chair, is scheduled to present these findings at the European Society for Medical Oncology (“ESMO”) Gastrointestinal Cancers Congress in Barcelona, Spain, on 2 July, 2025.","length":623,"tagName":"p"},{"type":"text","content":"The ASCEND trial is a 158-patient, double-blind, randomized, placebo-controlled Phase 2b clinical trial evaluating standard-of-care (“SoC”) gemcitabine and nab-paclitaxel vs SoC plus certepetide or placebo in patients with metastatic pancreatic ductal adenocarcinoma (“mPDAC”). Participants were enrolled from 24 sites across Australia and Aotearoa New Zealand from May 2022 to December 2023. The study comprises two sequentially enrolled dosing regimens of either certepetide or placebo in combina...